May 18, 2020 09:15 AM EDTUpdated May 19, 05:27 PM

AstraZeneca nabs breakthrough status, as $7B ADC races to blockbuster status

Jason Mast

Editor

A rapid breast cancer approval came just before New Year’s for AstraZeneca and Daiichi Sankyo’s billion-dollar antibody drug conjugate Enhertu, but the plan was …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca nabs breakthrough status, as $7B ADC races to blockbuster status

Jason Mast

Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Merck pays $30M to buy ‘chameleon’ approach to deadly brain cancers

Eye drop maker to merge with a retinal gene therapy startup from Spark co-founder

UK’s price watchdog says Lilly’s Alzheimer’s drug is too costly for broad uptake

Corrected: Sangamo to seek accelerated approval for Fabry gene therapy, claims it won't need confirmatory study

Amgen preps to launch Eylea biosimilar years early after Regeneron loses appeal

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

As­traZeneca nabs break­through sta­tus, as $7B ADC races to block­buster sta­tus

Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

AstraZeneca nabs breakthrough status, as $7B ADC races to blockbuster status